ONXX Related Earnings News
-
Onyx Pharmaceuticals, Inc. (ONXX) Reports Much Smaller Q1 Loss
-
Jefferies Lifts PT on Onyx Pharmaceuticals (ONXX) to $104
-
Jefferies Trims PT on Onyx Pharmaceuticals (ONXX) Post Q4
-
Onyx Pharmaceuticals, Inc. (ONXX) Posts Q4 Loss of $0.36/Sh
-
Onyx (ONXX) Updates on FY12 Ops, Achievements; Plans Kyprolis Phase 3 in FY13
-
Onyx Pharma's (ONXX) Kyprolis 'Killin It'
-
Onyx Pharmaceuticals (ONXX) May Have Untapped Opportunity in Frontline Multiple Myeloma
-
Pure Bioscience, Inc. (PURE) Reports Q1 Loss of $0.25
-
Baird Slaps $99 Price Target on Onyx Pharmaceuticals (ONXX)
-
Onyx Pharmaceuticals, Inc. (ONXX) Tops Q3 EPS by 11c
-
Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); Raising Kyprolis Estimates
-
Baird Reiterates an 'Outperform' on Onyx Pharmaceuticals (ONXX); Kyprolis Uptake and Take-out Potential
-
Onyx Pharmaceuticals, Inc. (ONXX) Posts Wider than Expected Q2 Loss of 68c/Share
-
Cantor Fitzgerald Maintains a 'Buy' on Ligand Pharma (LGND); Key Partnered Drug is Approved
-
Jefferies Upgrades Onyx Pharmaceuticals (ONXX) to Buy; FDA Approves Kyprolis; Takeover Speculation Intensifies
-
Barclays Raises Price Target on Onyx Pharmaceuticals (ONXX); Kyprolis Gets Surprisingly Supportive Commentary
-
Jefferies Adjusts Estimates and Price Target on Onyx Pharmaceuticals (ONXX); Downside Scenarios Reviewed
-
Brean Murray Carret & Co. Upgrades Onyx Pharmaceuticals (ONXX) to Buy; Misleading Documents...FDA Approval Is Coming
-
Goldman Sachs Raises Price Target on Onyx Pharma (ONXX) after FDA Panel Backs CFZ
-
Barclays Maintains an 'Equalweight' on Onyx Pharmaceuticals (ONXX); Facing Uphill Battle
-
Goldman Sachs Removes Onyx Pharmaceuticals (ONXX) from Conviction Buy List
-
Onyx Pharmaceuticals, Inc. (ONXX) Misses Q1 EPS by 13c
-
Onyx Pharmaceuticals, Inc. (ONXX) Reports Stronger-Than-Expected Q4 Results
-
Onyx Pharmaceuticals, Inc. (ONXX) Posts Q3 Loss of $0.31, Sales Fall Short
-
Onyx Pharmaceuticals (ONXX) Misses Q2 EPS Views; Revs Light
-
Onyx Pharma (ONXX) Posts Narrower than Expected Q1 Loss
-
Onyx Pharmaceuticals Inc. (ONXX) Reports Q4 Loss of 28c
-
Onyx Pharma (ONXX) Reports Q3 EPS of $0.66
-
Onyx Pharma (ONXX) Posts Q2 EPS of $0.05, Tops by 2c
-
Onyx Pharma (ONXX) Posts Q1 Loss of $0.02, Wider than Views
-
Onyx Pharma (ONXX) Misses Street's Q4 Views
-
Traders Shrug Off Better-Than-Expected Earnings as Onyx Pharma (ONXX) Announces 4M Share Offering
-
Onyx Pharma (ONXX) Reports Q1 Adj-EPS of $0.14, Misses by 3c
-
Onyx Pharmaceuticals (ONXX) Reports Q4 Loss
-
Onyx Pharmaceuticals (ONXX) Reports Q4 Adj-Los sof $0.45, Beats by 12c
-
Onyx Pharmaceuticals (ONXX) Reports Q2 Loss of $0.22
-
Onyx Pharmaceuticals (ONXX) Reports Q1 Loss of $0.26
Back to ONXX Stock Lookup
